肺がん患者における化学療法後の最善の支持療法と比較したアテゾリズマブ（MPDL3280A）の安全性と有効性を評価する研究 [IMpower010]

基本情報

NCT ID

NCT02486718

ステータス

実施中（募集終了）

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

1,280

治験依頼者名

Hoffmann-La Roche

概要

This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.

対象疾患

介入

依頼者（Sponsor）

実施施設 (19)